GlassScriptPhysician profile
Austin M Fraser
NPI 1336339118
$11,663.84
in general payments reported to CMS, 2019-2025
23 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,569 · 2020: $529 · 2021: $1,093 · 2022: $1,935 · 2023: $2,459 · 2024: $2,318 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,044 · Education: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,044.06 |
| Education | $493.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,795.26 | 2019-2025 | |
| Amgen INC. | $2,361.86 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $1,159.41 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $829.37 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $806.88 | 2019-2025 | |
| Pfizer INC. | $745.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $460.92 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $367.46 | 2019-2023 | Taltz |
| Aurinia Pharma U.S., INC. | $351.33 | 2023-2025 | Lupkynis |
| Genentech, INC. | $299.70 | 2024 | Actemra |
| Genzyme Corporation | $279.87 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $230.56 | 2019-2025 | Orencia |
| Genentech USA, INC. | $207.26 | 2019-2025 | Actemra, Gazyva |
| Astrazeneca Pharmaceuticals LP | $187.76 | 2021-2025 | Saphnelo |
| Regeneron Healthcare Solutions, INC. | $181.71 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $99.94 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $88.60 | 2022 | |
| Antares Pharma, INC. | $68.83 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.49 | 2022 | |
| Celgene Corporation | $41.89 | 2019 | |
| Hikma Pharmaceuticals USA | $18.65 | 2019 | |
| Oxford Immunotec USA INC | $17.29 | 2019 | |
| Radius Health, INC. | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Fraser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.